Clinical Trial

Cardiometabolic Effects of the Recommended Daily Pecan Intake Dose

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Cardiovascular disease risk factors, including higher BMIs and poor cholesterol profiles, are on the rise and contribute to the United States' growing disease burden. The bioactive compounds contained in tree nuts have been shown to beneficially affect cardiometabolic health outcomes. Pecans contain more total phenols, sterols, and flavonoids than any other tree nut. They also are a rich source of polyunsaturated fatty acids (PUFAs), fiber, vitamin A, vitamin E, folic acid, calcium, magnesium, phosphorus, potassium, and zinc. These bioactive components in pecans are likely the reason for the previously documented improvements in cardiometabolic health. This study aims to examine the impact of a low dose of pecans on changes in fasting and postprandial lipid metabolism/blood lipids and markers of chronic disease risk. The specific aims of this study are to: * Examine the effect of pecan consumption at a dose of 6% of total energy needs for 12 weeks on fasting and postprandial blood lipids. * Examine the effect of pecan consumption at a dose of 6% of total energy needs for 12 weeks on other markers of chronic disease risk. Participants will be asked to: * Consume pecans daily for 12 weeks or maintain their current habitual diet. * Attend two short visits at 4 and 8 weeks for fasting blood draws, body measurements, and to collect their next 4 weeks' supply of study materials. * Attend two longer (5 h) testing visits, which include eating a standard breakfast meal and having their blood drawn periodically before and after breakfast. Researchers will compare the Pecan and Control groups to examine the physiologic effects of incorporating a low dose of pecans into one's diet.
Protocol Amendment History 4 changes
critical Primary endpoint(s) modified 2026-08-12
notable Primary completion pushed: 2028-12 -> 2029-07 2026-08-12
minor Completion pushed: 2029-07 -> 2030-02 2026-08-12
critical Primary endpoint(s) modified 2026-07-14
Trial Details
NCT Number NCT07696403
Lead Sponsor University of Georgia
Conditions Nutrition, Healthy, Dyslipidemia, Overweight and Obesity
Enrollment 90 participants
Start Date 2027-03
Primary Completion 2029-07 (estimated)
Study Completion 2030-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-11